U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula O.Zn
Molecular Weight 81.395
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC OXIDE

SMILES

[O-2].[ZnH2+2]

InChI

InChIKey=RNWHGQJWIACOKP-UHFFFAOYSA-N
InChI=1S/O.Zn/q-2;+2

HIDE SMILES / InChI
Zinc oxide is an inorganic compound with the formula ZnO. ZnO is a white powder that is insoluble in water, and it is widely used as an additive in numerous materials and products including rubbers, plastics, ceramics, glass, cement, lubricants, paints, ointments, adhesives, sealants, pigments, foods, batteries, ferrites, fire retardants, and first-aid tapes. Although it occurs naturally as the mineral zincite, most zinc oxide is produced synthetically. Zinc oxide is widely used to treat a variety of skin conditions, including dermatitis, itching due to eczema, diaper rash and acne. It is used in products such as baby powder and barrier creams to treat diaper rashes, calamine cream, anti-dandruff shampoos, and antiseptic ointments. It is also a component in tape (called "zinc oxide tape") used by athletes as a bandage to prevent soft tissue damage during workouts. Zinc oxide can be used in ointments, creams, and lotions to protect against sunburn and other damage to the skin caused by ultraviolet light (see sunscreen). It is the broadest spectrum UVA and UVB absorber that is approved for use as a sunscreen by the U.S. Food and Drug Administration (FDA), and is completely photostable. When used as an ingredient in sunscreen, zinc oxide blocks both UVA (320–400 nm) and UVB (280–320 nm) rays of ultraviolet light. Zinc oxide and the other most common physical sunscreen, titanium dioxide, are considered to be nonirritating, nonallergenic, and non-comedogenic. Zinc oxide nanoparticles can enhance the antibacterial activity of ciprofloxacin. It has been shown that nano ZnO which has the average size between 20 nm and 45 nm can enhance the antibacterial activity of ciprofloxacin against Staphylococcus aureus and Escherichia coli in vitro. The enhancing effect of this nanomaterial is concentration dependent against all test strains. This effect may be due to two reasons. First, zinc oxide nanoparticles can interfere with NorA protein, which is developed for conferring resistance in bacteria and has pumping activity that mediate the effluxing of hydrophilic fluoroquinolones from a cell. Second, zinc oxide nanoparticles can interfere with Omf protein, which is responsible for the permeation of quinolones into the cell.

Originator

Curator's Comment:: The use of pushpanjan, probably zinc oxide, as a salve for eyes and open wounds, is mentioned in the Indian medical text the Charaka Samhita, thought to date from 500 BC or before. Zinc oxide ointment is also mentioned by the Greek physician Dioscorides (1st century AD.)

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: ultraviolet B-induced damage
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

-4.55328006E11
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Secondary
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

1.32675836E12
Primary
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

1.140048E12
Primary
ZINC OXIDE

Approved Use

Unknown
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
PubMed

PubMed

TitleDatePubMed
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.
1991 Apr 1
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1.
1991 Sep 10
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.
1993 Aug
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.
1994 Dec
New applications for the zinc iodide-osmium tetroxide technique.
1994 Feb
Iron chelators as therapeutic agents against Pneumocystis carinii.
1994 May
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.
1995 Nov 13
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
1997 Feb
Thujaplicin-copper chelates inhibit replication of human influenza viruses.
1998 Aug
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study.
1999 May
Inhibition of HIV-1 infection by zinc group metal compounds.
1999 Sep
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.
2000 Sep
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.
2004 Jul 16
High-throughput computational and experimental techniques in structural genomics.
2004 Oct
Impact of the mother's zinc deficiency on the woman's and newborn's health status.
2005
Erythrocyte zinc content in critically ill patients.
2005
Zinc in attention-deficit/hyperactivity disorder.
2005 Aug
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet.
2005 Nov-Dec
Characterization and inhibition of SARS-coronavirus main protease.
2006
Zinc nutritional status of morbidly obese patients before and after Roux-en-Y gastric bypass: a preliminary report.
2006 Apr
Copper and zinc concentrations in serum of healthy Greek adults.
2006 Apr 15
Effect of end-stage renal disease and diabetes on zinc and copper status.
2006 Jul
Elevated cortical zinc in Alzheimer disease.
2006 Jul 11
The effect of Ramadan on maternal nutrition and composition of breast milk.
2006 Jun
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality.
2006 May
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.
2006 May
On the mechanism of the conversion of methanol to 2,2,3-trimethylbutane (triptane) over zinc iodide.
2006 Nov 10
Zinc homeostasis in aging: two elusive faces of the same "metal".
2006 Summer
Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity.
2010 Dec
Glucarpidase following high-dose methotrexate: update on development.
2010 Jan
Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.
2011 Jun
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.
2012 Mar
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012 May 5
Glucarpidase for the treatment of life-threatening methotrexate overdose.
2012 Nov
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.
2013 Dec
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.
2013 Dec
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013 Jul 31
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.
2013 Sep
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014 Apr
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.
2014 Jul 1
Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
2014 May
Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.
2014 May 15
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.
2014 May 16
Ultrasonic assisted removal of sunset yellow from aqueous solution by zinc hydroxide nanoparticle loaded activated carbon: Optimized experimental design.
2015
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process.
2016 Oct
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016 Sep
Patents

Sample Use Guides

Recommended Dietary Allowance (RDA)-expressed as elemental zinc: 19 years and older: Male: 11 mg (Upper intake limit: 34 mg); Female: 9 mg (Upper intake limit: 34 mg); Pregnancy: 11 mg (Upper intake limit: 40 mg); Lactation: 12 mg (Upper intake limit: 40 mg) Zinc sulfate injection: IV: Metabolically stable adults receiving TPN: 2.5 to 4 mg zinc/day Acute catabolic states on TPN: Additional 2 mg zinc per day is recommended. Stable adult with fluid loss from the small bowel: Additional 12.2 mg zinc/liter of small bowel fluid lost, or an additional 17.1 mg zinc/kg of stool or ileostomy output is recommended.
Route of Administration: Other
HeLa, COS-7, and HEK293-T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen) supplemented with 10% fetal calf serum (FCS, Invitrogen), glutamine (2 mM), penicillin (100 units/mL), and streptomycin (100 μg/mL). Two days before imaging, the cells were passed and plated on untreated (HeLa, COS-7) 10-mm glass coverslips or on glass coverslips coated with 0.2% gelatin for at least 1 h at room temperature (HEK293-T). For labeling, the growth medium was removed and replaced with DMEM containing 1% FCS. The cells were treated and incubated with 10 μM sensor at 37 °C under 5% CO2 for 30 min. The cells were washed once with and bathed in DMEM containing no FCS prior to imaging and/or zinc addition. Zinc was introduced to the cultured cells as the pyrithione salt using a Zn (II)/pyrithione ratio of 1:1 or 1:2. Stock solutions of ZnCl2 (10 mM) and sodium pyrithione (20 mM) in DMSO were combined and diluted 10-fold with DMEM prior to addition. In a typical experiment, a 100-μL aliquot of this solution was added to the cells bathed in 2 mL of DMEM. A stock solution of TPEN (10 or 20 mM) was also diluted 10-fold with DMEM containing no FCS prior to cell treatment.
Name Type Language
ZINC OXIDE
EP   FCC   HSDB   II   INCI   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INCI  
Official Name English
ZINC OXIDE COMPONENT OF VUSION
Common Name English
ZINC OXIDE [WHO-DD]
Common Name English
C.I. 77947
Common Name English
ZINC OXIDE [USP-RS]
Common Name English
ZINC WHITE
Common Name English
ZINC (AS ZINC OXIDE) [VANDF]
Common Name English
ZINC OXIDE COMPONENT OF CALAMINE
Common Name English
CALAMINE COMPONENT ZINC OXIDE
Common Name English
CI 77947
INCI  
INCI  
Official Name English
C.I. PIGMENT WHITE 4
Common Name English
ZINCUM OXYDATUM
HPUS  
Common Name English
ZINC OXIDE NEUTRAL [USP MONOGRAPH]
Common Name English
ZINC OXIDE [MART.]
Common Name English
ZINC OXIDE EMULSION [VANDF]
Common Name English
ZINC OXIDE [WHO-IP]
Common Name English
ZINC PASTE [VANDF]
Common Name English
ZINC OXIDE [HSDB]
Common Name English
ZINC OXIDE [INCI]
Common Name English
ZINC OXIDE [ORANGE BOOK]
Common Name English
ZINC OXIDE [FCC]
Common Name English
ZINC OXIDE [EP MONOGRAPH]
Common Name English
ZINC OXIDE [II]
Common Name English
ZINCI OXYDUM [WHO-IP LATIN]
Common Name English
ZINC OXIDE [JAN]
Common Name English
ZINC OXIDE [VANDF]
Common Name English
CI 77947 [INCI]
Common Name English
ZINC (AS OXIDE) [VANDF]
Common Name English
VUSION COMPONENT ZINC OXIDE
Common Name English
ZINC OXIDE [USP]
Common Name English
ZINC PASTE
VANDF  
Common Name English
ZINC OXIDE [MI]
Common Name English
ZINCUM OXYDATUM [HPUS]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 178.3297
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 175.300
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 175.380
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 177.1460
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 177.1900
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
FDA ORPHAN DRUG 142401
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 310.531
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 352.20
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 352.10
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
WHO-VATC QA07XA91
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 193
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
EPA PESTICIDE CODE 88502
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 347.10
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
NCI_THESAURUS C851
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 346.18
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 177.1350
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 176.170
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
Code System Code Type Description
DRUG BANK
DB09321
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
MERCK INDEX
M11617
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY Merck Index
PUBCHEM
3007857
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
WIKIPEDIA
ZINC OXIDE
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ZINC OXIDE
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY Description: A white or faintly yellowish white, very fine, amorphous powder, free from grittiness; odourless. Solubility: Practically insoluble in water and ethanol (~750 g/l) TS; soluble in hydrochloric acid (~70 g/l) TS. Category: Mild astringent used topically as a protective. Storage: Zinc oxide should be kept in a well-closed container. Additional information: Zinc oxide gradually absorbs carbon dioxide from the air. Definition: Zinc oxide contains not less than 99.0% and not more than 100.5% of ZnO, calculated with reference to the freshly ignited substance.
EVMPD
SUB12623MIG
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
EPA CompTox
1314-13-2
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
MESH
D015034
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
DRUG CENTRAL
4240
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
USP_CATALOG
1724747
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY USP-RS
NCI_THESAURUS
C949
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
HSDB
5024
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
RXCUI
11423
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY RxNorm
CAS
1314-13-2
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201128
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
FDA UNII
SOI2LOH54Z
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
ECHA (EC/EINECS)
215-222-5
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY